MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Bioequivalence & Bioavailability International Journal
ISSN: 2578-4803

Applications of Artificial Intelligence in Pharmaceutical Research: An Extensive Review

Nihalani G[1#]* and Pawar HA[2#]

[1]Research Fellow, Teva Pharmaceuticals, USA

[2]Department of Pharmacognosy, Dr. L. H. Hiranandani College of Pharmacy, India

***Corresponding author:** Girish Nihalani, Research Fellow, Teva Pharmaceuticals, USA, Email: girlani679@gmail.com

[#]equally contributed towards this manuscript

Review Article

Volume 8 Issue 1

Received Date: March 30, 2024

Published Date: May 07, 2024

DOI: 10.23880/beba-16000231

Abstract

Artificial Intelligence (AI) is transforming the pharmaceutical industry, revolutionizing drug discovery, development, and patient care. This comprehensive review explores the diverse applications of AI in the pharmaceutical sector, discussing its advantages, challenges, and future prospects. AI-driven techniques, including machine learning and deep learning, have accelerated drug discovery processes by expediting target identification, virtual screening, and drug repurposing. Predictive analytics optimize clinical trial design, while personalized medicine leverages patient-specific data for precise treatment plans. AI enhances drug formulation and manufacturing, improves pharmacovigilance and drug safety, and supports drug pricing and market access strategies. Despite its potential, challenges such as ethical considerations and data privacy concerns must be addressed. The integration of AI into existing workflows and regulatory compliance remain areas of focus. By overcoming these challenges, AI stands poised to reshape the pharmaceutical industry and pave the way for a more efficient, personalized, and impactful approach to drug development and healthcare.

Keywords: Artificial Intelligence; Drug Development; Pharmaceutical Industry; Drug Discovery; Drug Repurposing

Abbreviations: AI: Artificial Intelligence; ML: Machine Learning; MGI: Mckinsey Global Institute; FDA: Food and Drug Administration; GDPR: General Data Protection Regulation; HIPAA: Health Insurance Portability and Accountability Act.

Introduction

In today's world, AI has become an inseparable part of our present and future [1]. Due to the advances in computational power and the enormous amounts of digitalization, there is an ever-increasing wealth of data. AI uses the power of algorithms (computer programs) to make inferences by finding features from large amounts of data. Ultimately, the programming of the algorithm is in the hands of the scientists and clinicians who set up the underlying instructions that help the computer make decisions, such as classification. Hence, the algorithms are often based on information and understanding that we, humans, already have (supervised methods) so that predictions can be made using this knowledge. On the other hand, unsupervised methods from machine learning (ML) are where the algorithm manages to learn, analyze, and make inferences from data without human involvement. Thus, in case of a vast field such as precision oncology, there is great value in an open-ended approach such as ML, especially unsupervised algorithms. It would allow the practitioner to "see" information that may not have been evident to them directly. In addition, ML being independent in learning improves as more data become available. Artificial Intelligence (AI) is an interdisciplinary field that focuses on the development of intelligent machines capable of performing tasks that typically require human intelligence [2]. In recent years, AI has gained significant traction in the pharmaceutical industry due to its potential to optimize drug discovery and development processes and

improve patient outcomes. Numerous industries are actively pursuing strategies to boost their progress in order to meet the ever-evolving demands and expectations of their customers. Among these sectors, the pharmaceutical industry holds a crucial position, playing a pivotal role in saving lives. With a strong focus on continuous innovation and the adoption of cutting-edge technologies, the pharmaceutical industry is at the forefront of addressing global healthcare challenges and responding to medical emergencies, such as the recent pandemic [3]. Innovation within the pharmaceutical sector is driven by extensive research and development efforts across diverse domains, including advanced manufacturing technologies, innovative packaging solutions, and customer-centric marketing strategies [4]. From the development of small drug molecules to biologics, there is a consistent emphasis on enhancing stability and potency to meet unmet medical needs. However, the evaluation of the potential toxicity associated with new drugs remains a significant concern, necessitating ongoing research and exploration. A primary objective is to deliver drug molecules that offer optimal benefits and suitability for use in the healthcare industry. Despite advancements, the pharmaceutical industry encounters various challenges that require further technological advancements to meet global medical and healthcare demands [5]. The demand for a skilled workforce in the healthcare sector is persistent, underscoring the importance of providing continuous training to healthcare personnel to enhance their effectiveness in routine tasks. Identifying skill gaps within the pharmaceutical industry is crucial, and addressing these gaps through appropriate remedial measures is essential. However, providing adequate training presents its own challenges. According to a report by certain authorities, approximately 41% of supply chain disruptions occurred in June 2022, making supply chain disruption the second most formidable challenge faced by the industry. Many pharmaceutical companies are anticipating further advancements in their supply chain and exploring innovative models to overcome these challenges, thereby enhancing business resilience [6]. The global outbreak of the coronavirus disease 2019 (COVID-19) has caused significant disruptions to various operations worldwide, including ongoing clinical trials [7]. These disruptions have underscored the importance of resilience and adaptability within the pharmaceutical industry as it continues to navigate through uncertain times. FDA plans to develop and adopt a flexible risk-based regulatory framework that promotes innovation and protects patient safety as AI/ML will undoubtedly play a critical role in drug development. The McKinsey Global Institute (MGI) has estimated that technology could generate $60 billion to $110 billion a year in economic value for the pharma and medical-product industries, because it can boost productivity by accelerating the process of identifying compounds for possible new drugs, speeding their development and approval, and improving the way they are marketed.

Advantages of AI in the Pharmaceutical Industry

AI offers several advantages in the pharmaceutical industry. Firstly, it accelerates the drug discovery and development processes by streamlining data analysis and prediction algorithms. Secondly, it enhances target identification and validation, allowing researchers to pinpoint potential drug targets more accurately. Thirdly, AI enables personalized treatment approaches by analyzing patient-specific data to tailor treatments accordingly. Additionally, it improves clinical trial design and efficiency by optimizing patient recruitment rates and predicting outcomes. Lastly, AI enhances pharmacovigilance and drug safety surveillance by analyzing adverse drug reaction data from various sources, contributing to safer and more effective medications.

Digim I2s Software

Digim is an example of a tool/service provided by digimsolution to assist in drug development which can significantly reduce the drug development time. I2S utilizes artificial intelligence techniques to support digital transformation of drug products. The technique is basically based on analysis of structure at micro level and determining various parameters. Through machine learning and deep learning semantic image segmentation techniques, I2S offers the tools to handle mage analysis problem. For quantifications, morphological characterizations such as volume, particle size distribution, and spatial distributions can be performed to determine metrics. By using data of these measured attributes, once can correlate microstructural critical quality attribute to process parameters and product performance to gain a greater understanding of their products. For Physics-based Simulations, it features a suite of physics based simulations allowing to compute mass transport properties of product directly from their imagery. digiM has developed a voxel based simulation method, in which each pixel of the scene is used as a computational cells to assist in these computations. This voxel based approach allows I2S users to compute highly accurate mass transport properties much faster than traditional fluid dynamics simulation techniques. I2S also contains a patented diffusion simulation allowing users to predict the drug release of the digital twins of their products. The microporous structure analysis by imaging can also be used to quantity the amount of crystallinity in amorphous solid dispersion. In an study by digiM, X-ray microscopy and artificial intelligence (AI) image segmentation were applied to quantify the critical quality attributes of API particles. Through quantitative analysis, mechanistic understandings of drug release mechanisms were uncovered, and the root cause of in vitro release testing differences was discovered [8].

AI Applications in Drug Discovery

The use of artificial intelligence (AI) in medicinal chemistry has gained significant attention in recent years as a potential means of revolutionizing the pharmaceutical industry [9]. Drug discovery, the process of identifying and developing new medications, is a complex and time-consuming endeavor that traditionally relies on labor-intensive techniques, such as trial-and-error experimentation and high-throughput screening. However, AI techniques such as machine learning (ML) and natural language processing offer the potential to accelerate and improve this process by enabling more efficient and accurate analysis of large amounts of data [10]. The successful use of deep learning (DL) to predict the efficacy of drug compounds with high accuracy has been described recently by the authors LeCun Y, et al. [11]. AI-based methods have also been able to predict the toxicity of drug candidates [12]. These and other research efforts have highlighted the capacity of AI to improve the efficiency and effectiveness of drug discovery processes. However, the use of AI in developing new bioactive compounds is not without challenges and limitations. Ethical considerations must be taken into account, and further research is needed to fully understand the advantages and limitations of AI in this area [13]. Despite these challenges, AI is expected to significantly contribute to the development of new medications and therapies in the next few years. Per one report from McKinsey and company, titled "Generative AI in the pharmaceutical industry: Moving from hype to reality", for In silico compound screening, Gen AI accelerates the screening process with foundational chemistry models that can map millions of known chemical compounds by their structure and function and overlay this information with known results for tested molecules. Like GPT-4, which is trained to predict the likely next word in a sentence, these models predict the next part (for example, an atom) in the structure of small or large molecule (such as an amino acid). Through much iteration, the model learns fundamental principles of large and small molecule chemistry. This knowledge can then be used to train bespoke machine learning models that offer more precise predictions in largely unexplored areas of chemistry that companies can prioritize for subsequent screening.

AI-Enabled Drug Repurposing

Machine learning plays an important role in studying drug repurposing, especially since the occurrence of COVID-19, scientists around the world used machine learning-based approaches to signal effective drugs. At present, there are still some problems, such as the black box problem of deep learning to signaling repurposable drugs causing hard to explain the rationality of the results. It is necessary to develop interpretable deep learning and causal learning along with the traditional drug discovery experiments. Furthermore, it is the fusion problem of the general field of machine learning in drug development, how to better characterize molecules and their conformational changes, to better extract the characteristics of molecules. By developing machine learning methods, we can accelerate drug discovery and improve human health in a way that has never been possible before. AI-driven approaches are facilitating drug repurposing efforts by identifying existing drugs that could be effective against new diseases or indications. This strategy accelerates the drug development timeline and reduces costs [14,15].

AI in Predictive Analytics for Clinical Trials

Clinical trial analytics is crucial for advancing healthcare outcomes globally. The use of machine learning in clinical trial analytics holds promise for accelerating processes, enhancing patient stratification, and advancing precision medicine. Challenges remain, such as the need for high-quality, non-biased training data, which can unleash the potential of machine learning, while balancing privacy concerns. Addressing these challenges in a thoughtful and ethical manner will pave the way for more effective and inclusive clinical trial analytics, ultimately benefiting diverse patient populations and advancing the field of medical research. AI helps optimize clinical trial design by predicting patient recruitment rates, patient responses, and potential adverse events. This aids in improving trial efficiency and reducing costs [16,17]. By using generative AI models built on data from medical imaging techniques such as X-rays, CAT scans, and MRIs, scientists could identify new biomarkers, deeply hidden visual signatures of disease activity and severity that lead to unforeseen new treatments. The cumulative result will be shorter, more efficient trials with a greater likelihood of success [18].

AI in Personalized Medicine and Precision Oncology

AI algorithms are enabling the analysis of patient-specific data to develop personalized treatment plans based on a patient's unique genetic and molecular profile. The data-driven identification of disease states and treatment options is a crucial challenge for precision oncology. Artificial intelligence (AI) offers unique opportunities for enhancing such predictive capabilities in the lab and the clinic. AI, including its best-known branch of research, machine learning, has significant potential to enable precision oncology well beyond relatively well-known pattern recognition applications, such as the supervised classification of single-source omics or imaging datasets [19,20].

AI In Drug Manufacturing & Regulatory Compliance

AI is being utilized in drug formulation to predict optimal drug delivery systems and improve manufacturing processes, leading to enhanced drug stability and bioavailability [21,22]. AI algorithms analyze adverse drug reaction data from various sources, such as social media and electronic health records, to improve pharmacovigilance and drug safety surveillance [23,24]. AI is applied to analyze healthcare data and market dynamics, helping pharmaceutical companies optimize drug pricing strategies and ensure better market access [25,26]. AI can assist in the analysis of complex regulatory data, expediting the drug approval process and ensuring compliance with regulatory standards [27,28]. During the drug development process, pharma companies needs to answer questions and requests from regulatory agencies and they often create bottlenecks that can delay the approval and market entry of new therapies. Gen AI enabled intelligence engines can help predicting potential questions/requests patterns for a given submission; rapidly crafting appropriate responses; and providing deeper intelligence to submission strategies. Gen AI's predictive analytics can help teams proactively anticipate questions/requests, thus reducing their number, both initial and on follow-up. The insights generated will go on to inform regulatory strategy, risk management, and the broader R&D strategy [18].

Challenges and Future Considerations

Ethical Considerations and Data Privacy Concerns

Ethical considerations and data privacy concerns are paramount when implementing artificial intelligence (AI) in the pharmaceutical industry. As AI algorithms analyze sensitive patient data and make critical decisions, ensuring ethical conduct and protecting patient privacy are essential. Healthcare data often include personal information, medical history, and genetic data, raising concerns about confidentiality, consent, and data security.

To address these challenges, regulatory frameworks and guidelines have been established to govern the use of AI in healthcare. For example, the General Data Protection Regulation (GDPR) in the European Union and the Health Insurance Portability and Accountability Act (HIPAA) in the United States mandate strict standards for data protection and privacy in healthcare settings. Compliance with these regulations is crucial to safeguarding patient rights and preventing unauthorized access or misuse of personal health information.

Furthermore, ethical considerations extend beyond data privacy to encompass broader issues such as algorithmic bias, transparency, and accountability. AI algorithms may inadvertently perpetuate biases present in training data, leading to disparities in healthcare outcomes across different demographic groups. Ensuring fairness and equity in AI applications requires ongoing monitoring, bias mitigation strategies, and transparency in algorithmic decision-making processes [27-29].

Integration of AI into Existing Workflows and Processes

Integrating AI into existing workflows and processes poses significant challenges for pharmaceutical companies, healthcare providers, and other stakeholders. AI implementation requires seamless integration with existing IT systems, data infrastructure, and clinical workflows to ensure interoperability and usability.

One of the key challenges is the compatibility of AI solutions with legacy systems and data formats. Pharmaceutical companies may need to invest in infrastructure upgrades, data standardization efforts, and interoperability solutions to enable effective integration of AI technologies into their operations.

Moreover, organizational culture, resistance to change, and workforce readiness are critical factors influencing the successful integration of AI into existing workflows. Training and upskilling employees, fostering a culture of innovation and collaboration, and addressing resistance to technological change are essential for driving successful AI adoption.

Collaboration between AI developers, IT professionals, and domain experts is crucial for identifying workflow inefficiencies, designing AI solutions tailored to specific use cases, and ensuring seamless integration with existing processes. Continuous feedback loops, iterative improvements, and user-centric design principles are essential for optimizing AI deployment and maximizing its impact on pharmaceutical operations [30-32].

Validation and Interpretability of AI Models in Highly Regulated Environments

In highly regulated environments such as the pharmaceutical industry, validating and interpreting AI models pose significant challenges. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) require rigorous validation and documentation of AI algorithms to ensure their safety, efficacy, and reliability.

One of the key challenges is establishing the validity and generalizability of AI models across diverse patient populations and clinical settings. Robust validation studies, real-world evidence generation, and post-market surveillance are essential for demonstrating the performance and safety of AI-driven solutions in real-world scenarios.

Interpretability of AI models is another critical aspect, especially in healthcare contexts where transparent decision-making is essential for gaining clinician trust and acceptance. Explainable AI (XAI) techniques such as model-agnostic methods, feature importance analysis, and interactive visualization tools can enhance the interpretability of AI models and facilitate human-AI collaboration.

Furthermore, ensuring regulatory compliance and alignment with existing standards and guidelines is essential for gaining regulatory approval and market acceptance. Collaborative efforts between AI developers, pharmaceutical companies, and regulatory authorities are crucial for establishing regulatory frameworks, standards, and best practices for validating and interpreting AI models in highly regulated environments [33-35].

Collaborative Efforts between AI Developers, Pharmaceutical Companies and Regulatory Authorities

Collaborative efforts between AI developers, pharmaceutical companies, and regulatory authorities are essential for advancing the responsible development and deployment of AI-driven solutions in healthcare. Stakeholder collaboration facilitates knowledge sharing, technology transfer, and regulatory alignment, enabling faster innovation and adoption of AI in pharmaceutical research and development.

Pharmaceutical companies play a crucial role in providing domain expertise, clinical data, and financial resources to support AI research and development initiatives. Collaborative partnerships with AI developers enable access to cutting-edge technologies, expertise, and novel methodologies for accelerating drug discovery, development, and regulatory approval processes.

Regulatory authorities play a pivotal role in establishing guidelines, standards, and regulatory frameworks for AI-driven healthcare products. Collaborative engagement with regulatory agencies facilitates early dialogue, regulatory alignment, and transparency, ensuring timely approval and market access for AI-driven solutions.

Moreover, multidisciplinary collaborations involving clinicians, researchers, policymakers, and patient advocates promote a holistic approach to AI development and deployment, considering clinical relevance, patient safety, and societal impact. By fostering open communication, shared goals, and mutual trust, collaborative efforts drive innovation, address regulatory challenges, and maximize the potential of AI to transform pharmaceutical research and healthcare delivery [36-38].

Conclusion

Artificial intelligence (AI) has emerged as a transformative force in the pharmaceutical industry, reshaping traditional approaches to drug discovery, development, and patient care. This extensive review has highlighted the myriad applications of AI in various facets of the pharmaceutical sector, emphasizing its advantages, challenges, and future prospects. From expediting drug discovery processes to optimizing clinical trial design, AI-driven techniques such as machine learning and deep learning have revolutionized pharmaceutical research. By leveraging vast datasets and predictive analytics, AI accelerates target identification, enhances drug repurposing efforts, and enables personalized treatment approaches tailored to individual patients' genetic and molecular profiles.

Moreover, AI plays a pivotal role in improving drug formulation and manufacturing processes, enhancing pharmacovigilance and drug safety surveillance, and supporting drug pricing and market access strategies. These advancements not only drive efficiency gains but also contribute to better healthcare outcomes and patient experiences. However, the integration of AI into existing workflows and regulatory compliance remains a challenge, necessitating collaborative efforts between AI developers, pharmaceutical companies, and regulatory authorities. Ethical considerations and data privacy concerns also require careful attention to ensure responsible AI deployment and safeguard patient interests. In conclusion, while AI holds immense promise for reshaping the pharmaceutical industry and advancing healthcare, addressing these challenges is crucial for realizing its full potential. With continued innovation, collaboration, and ethical oversight, AI stands poised to usher in a new era of precision medicine, driving impactful improvements in drug development and patient care on a global scale.

References

1. Krikorian G, Torreele E (2021) We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis. Health Hum Rights 23(1): 119-127.

2. Chavda VP, Vihol D, Patel A, Redwan EM, Uversky

VN (2023) Introduction to Bioinformatics, AI, and ML for Pharmaceuticals. Bioinformatics Tools for Pharmaceutical Drug Product Development, John Wiley & Sons Ltd, USA, pp: 1-18.

3. Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the Decline in Pharmaceutical R&D Efficiency. Nat Rev Drug Discov 11(3): 191-200.

4. Munos B (2009) Lessons from 60 Years of Pharmaceutical Innovation. Nat Rev Drug Discov 8(12): 959-968.

5. Mak KK, Pichika MR (2019) Artificial Intelligence in Drug Development: Present Status and Future Prospects. Drug Discov Today 24(3): 773-780.

6. (2023) Biggest Challenges Facing the Pharmaceutical Industry in 2023.

7. Chavda VP, Valu DD, Parikh PK, Tiwari N, Chhipa AS, et al. (2023) Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants. Vaccines 11(2): 374.

8. Technology: DigiM's I2S software.

9. Gao M (2020) A Comprehensive Review of Artificial Intelligence in Drug Discovery. Expert Opin Drug Discov 15(10): 1035-1047.

10. Jang H (2021) Artificial Intelligence in Drug Discovery: A Comprehensive Review. Biomedicines 9(5): 468.

11. LeCun Y (2015) Deep Learning in Biology. Cell 161(5): 1152-1165.

12. Xu H (2020) AI-Driven Drug Repurposing: The Quest for COVID-19 Therapeutics. Drug Discov Today 25(8): 1534-1538.

13. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, et al. (2016) Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Mol Pharm 13(7): 2524-2530.

14. Cabitza F (2016) Predictive Models for Imbalanced Data in Clinical Decision Support. Curr Bioinform 11(4): 428-443.

15. FDA (2021) Use of Artificial Intelligence in Drug Development and Review. U.S. Food and Drug Administration.

16. Offit K (2011) Personalized Medicine: New Genomics, Old Lessons. Hum Genet 130(1): 3-14.

17. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative Genomic Analyses Identify MITF as a Lineage Survival Oncogene Amplified in Malignant Melanoma. Nature 436(7047): 117-122.

18. McKinsey and Company (2024) Generative AI in the pharmaceutical industry: Moving from hype to reality.

19. Satyanarayana G (2020) Applications of Artificial Intelligence in Pharmaceutical Formulation Development. Pharmaceutics 12(11): 1096.

20. Ezzeldin E (2020) Applications of Artificial Intelligence in Drug Manufacturing. Pharmaceutics 12(11): 1054.

21. Patrizio E (2019) Pharmacovigilance for Herbal Medicines: A Systematic Review. Drug Saf 42(8): 961-975.

22. Yang CC (2015) Detection of Adverse Drug Reaction from Electronic Health Records Using Text Mining Technique. Comput Math Methods Med 2015: 1-9.

23. Mzoughi NA (2020) Using Artificial Intelligence Techniques for Healthcare Providers Market Analysis. Soft Comput 24(13): 9159-9174.

24. Wang J (2021) Artificial Intelligence in Drug Pricing: Opportunities and Challenges. Drug Discov Today 26(1): 238-245.

25. Khorasani-Zavareh D (2019) Artificial Intelligence Applications in Drug Regulatory Approval Process: The Challenges Ahead. Med Res Arch 7(1): 1-17.

26. Law S (2020) Artificial Intelligence in Drug Development: Present Status and Future Prospects. Drug Discov Today 25(8): 1525-1531.

27. Mittelstadt BD, Allo P, Taddeo M, Wachter S, Floridi L (2016) The ethics of algorithms: Mapping the debate. Big Data & Society 3: 1-21.

28. Obermeyer Z, Powers B, Vogeli C, Mullainathan S (2019) Dissecting racial bias in an algorithm used to manage the health of populations. Science 366(6464): 447-453.

29. Grande D, Mitra N, Shah A, Wan F, Asch DA (2013) Public preferences about secondary uses of electronic health information. Jama Intern Med 173(19): 1798-1806.

30. Raghupathi W, Raghupathi V (2014) Big data analytics in healthcare: promise and potential. Health Inf Sci Syst 2: 3.

31. Topol EJ (2019) High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine 25: 44-56.

32. Miliard M (2018) The future of EHRs: interoperability, artificial intelligence and personalized medicine. Healthcare IT News.

33. FDA (2021) Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan.

34. Beam AL, Kohane IS (2018) Big data and machine learning in health care. Jama 319(13): 1317-1318.

35. Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, et al. (2018) Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface 15(141): 20170387.

36. WHO (2021) Ethical Considerations to Guide the Use of Artificial Intelligence in Health Care.

37. European Commission (2020) White Paper on Artificial Intelligence: A European Approach to Excellence and Trust.

38. European Medicines Agency (2021) Regulatory Science strategy.